ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1455	National Cancer Institute	Html	en	Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Merkel cell carcinoma.	inadequate surgical margins 0.329956 cell polyomavirus infection. 0.336356 lymph node dissection 0.348903 Australian Merkel cell 0.385562 Distinct merkel cell 0.383584 neuroendocrine) carcinoma. 0.357189 node-positive Merkel cell 0.37626 Cell Carcinoma Information 0.370356 Ann Surg Oncol 0.393202 Rockville Merkel Cell 0.387174 clinical trials 0.331337 distant metastatic disease 0.331199 newly diagnosed patients 0.336848 cell carcinoma tumors 0.386769 Merkel cell cancer 0.385012 metastatic disease 0.334729 advanced merkel cell 0.38315 patients 0.398223 human Merkel cell 0.391488 Merkel cell polyoma 0.396025 lymph node biopsy 0.394484 sentinel lymph node 0.424128 Merkel tumours 0.360064 Merkel cell carcinomas 0.385298 primary Merkel cell 0.398409	et al. 0.396589 wide local excision 0.340871 case series 0.379017 Arch Dermatol 0.332282 cutaneous Merkel-cell carcinoma 0.356835 PUBMED Abstract 0.359039 adjuvant radiation therapy 0.370608 Invest Dermatol 0.331034 neuroendocrine-merkel cell carcinoma 0.369705 MCC patients 0.350161 Surg Oncol 0.397083 merkel cell carcinoma 0.931809 Abstract 0.399239 Clin Oncol 0.38708 cell polyomavirus sequences 0.331565 Dermatol Surg 0.33595 Carcinoma Group 0.350591 cell carcinoma demographics 0.372267 Trabecular carcinoma 0.351339 cell polyomavirus DNA 0.331118 lymph node 0.427173 cell carcinoma adjuvant 0.368757 merkel cell polyomavirus 0.477468 lymph node metastases 0.330714	CLICK HERE
1522	National Cancer Institute	Html	en	Childhood Brain Stem Glioma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood brain stem glioma.	PDQ Childhood Brain 0.262624 cancer treatment 0.317391 new cancer cells 0.250632 brain stem glioma 0.990842 metastatic brain tumors 0.262145 type 0.250835 PDQ cancer information 0.305049 clinical trial search 0.257718 brain tumors 0.389165 children 0.259907 clinical trials 0.541127 health care providers 0.255221 Pediatric Treatment Editorial 0.256101 cancer information summary 0.282392 clinical trial 0.361183 patients 0.252235 NCI PDQ cancer 0.25809 radiation therapy 0.3037 Treatment Editorial Board 0.258484 intrinsic pontine glioma 0.314731 focal childhood brain 0.250848 late effects 0.256779 treatment 0.494086 focal glioma 0.286058 cancer cells 0.359639	brain stem gliomas 0.410944 primary brain tumors 0.262357 PDQ Pediatric Treatment 0.253085 signs 0.25352 Benign brain tumors 0.261631 treatment clinical trials 0.275821 National Cancer Institute 0.282821 following PDQ treatment 0.270231 effects cancer treatment 0.263814 new treatment 0.290537 childhood cancer information 0.253956 childhood brain tumors 0.305915 BRAF kinase 0.259925 treatment clinical trial 0.25851 PDQ summary 0.250138 Malignant brain tumors 0.261555 cancer clinical trials 0.275926 focal brain stem 0.331856 treatment options 0.261824 brain tissue 0.259205 cancer 0.498153 standard treatment 0.287654 BRAF kinase inhibitor 0.253173 childhood brain stem 0.659927	CLICK HERE
1538	National Cancer Institute	Html	en	Coenzyme Q10 (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of coenzyme Q10 as a treatment for people with cancer.	cell respiration 0.339879 naturally occurring forms 0.338495 new blood cells 0.340323 United States 0.340183 plasma coenzyme 0.469789 clinical examination 0.347068 cell growth 0.340428 animal immune systems 0.339418 cancer cells 0.357416 above-mentioned human studies 0.339569 follow-up study 0.36193 quinone chemical group 0.341067 breast cancer prognosis. 0.348287 cellular energy production 0.369553 cancer therapy 0.341253 free radical damage 0.357523 dietary supplements 0.352656 blood levels 0.35773 IND application process 0.337121 anthracycline anticancer drug 0.341617 cancer information summary 0.355992 coenzyme q10 0.913438 free radicals 0.338619 anthracycline drug doxorubicin 0.340494	high-dose coenzyme 0.460691 uncontrolled clinical study 0.342321 clinical drug research 0.340343 specific disease prevention 0.33723 breast cancer patients 0.409089 adjuvant therapy 0.341472 animal studies 0.378869 Investigational New Drug 0.337296 important cellular components 0.338608 normal blood levels 0.341607 protective effect 0.341278 radiation therapy 0.379802 high-level coenzyme 0.453918 aerobic energy production 0.337109 Low blood levels 0.340721 indirect anticancer activity 0.337514 lung cancer cells 0.348538 single-dose radiation therapy 0.3393 standard therapy 0.337625 coenzyme Q10. 0.469116 benzoquinone compound 0.3465 follow-up study report 0.341395 original study 0.33952	CLICK HERE
1545	National Cancer Institute	Html	en	Adult Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.	red blood cells 0.404993 cancer treatment 0.406441 body 0.406679 PDQ cancer information 0.415705 unfavorable Hodgkin lymphoma 0.403766 Non-Hodgkin Lymphoma Treatment 0.396504 clinical trial search 0.387461 pregnant women 0.365816 favorable Hodgkin lymphoma 0.403909 white blood cells 0.390827 favorable adult Hodgkin 0.379079 unfavorable adult Hodgkin 0.379392 clinical trials 0.634552 lymph nodes 0.463894 cancer information summary 0.39389 clinical trial 0.489293 stem cell transplant 0.415484 recurrent Hodgkin lymphoma 0.402776 adult hodgkin lymphoma 0.802336 patients 0.379207 blood cells 0.446195 weight loss 0.391968 NCI PDQ cancer 0.365284 radiation therapy 0.587067 Nodular sclerosing Hodgkin 0.384149	lymph node groups 0.460532 treatment 0.56475 night sweats 0.39371 Hodgkin Lymphoma Treatment 0.422215 cancer cells 0.401875 cellularity Hodgkin lymphoma 0.419706 swollen lymph nodes 0.429808 treatment clinical trials 0.386111 National Cancer Institute 0.39221 lymph vessels 0.383555 new treatment 0.393163 advanced hodgkin lymphoma 0.435901 Hodgkin lymphomas 0.368401 classical Hodgkin lymphoma 0.419308 bone marrow 0.427904 depletion Hodgkin lymphoma 0.419209 sedimentation rate 0.371778 hodgkin lymphoma 0.94955 cancer clinical trials 0.401646 stage 0.410094 Combination chemotherapy 0.415703 cancer 0.682215 information 0.416232 appropriate cancer treatment 0.37213	CLICK HERE
1725	National Cancer Institute	Html	en	Inflammatory Breast Cancer	A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm.	breast cancer talk 0.38738 ongoing clinical trials 0.322108 breast cancer biology 0.384329 Cancer Treatment Research 0.336489 MS. Inflammatory breast 0.412908 clinical trials 0.369256 Post-mastectomy radiation therapy 0.322454 breast size 0.368687 peau d'orange 0.322535 primary inflammatory breast 0.413233 adjuvant therapy 0.323679 inflammatory breast cancers 0.456146 neoadjuvant chemotherapy 0.327114 entire affected breast 0.371358 cancer recurrence 0.326653 radiation therapy 0.339981 Adjuvant systemic therapy 0.323571 Cancer Survival 0.32586 Cancer Journal 0.32501 invasive breast cancers 0.36818 women 0.331101 sponsors clinical trials 0.32312 Breast reconstruction 0.363182 multimodal approach 0.325682 cancer cells 0.367244	Breast Diseases 0.36337 M. Inflammatory breast 0.415692 HER2-positive breast cancer 0.393048 National Cancer Database 0.332281 nci-supported clinical trials 0.33341 National Cancer Institute 0.374989 hormone therapy 0.325328 estrogen-dependent cancer cells 0.336098 breast carcinoma incidence 0.386211 African American women 0.324285 Inflammatory breast tumors 0.439717 lymph vessels 0.32463 cancer detection 0.328538 neoadjuvant HER2-directed therapy 0.322104 inflammatory breast carcinoma 0.435431 dense breast tissue 0.375347 abnormal breast warmth 0.375148 inflammatory breast cancer 0.961199 Swollen lymph nodes 0.324354 cancer clinical trials 0.346503 Clinical Cancer Research 0.336483 postoperative radiation therapy 0.322326 et al 0.375354 cancer patient 0.327473	CLICK HERE
1935	National Cancer Institute	Html	es	Tratamiento del ependimoma infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil.	radiocirugía estereotáctica 0.685192 siguientes procedimientos 0.332065 efectos secundarios meses 0.562136 siguientes áreas 0.378745 huesos dorsales 0.375848 general recidiva 0.34956 efectos tardíos 0.729968 PDQ Efectos tardíos 0.453185 cabo irm 0.352274 líquido cefalorraquídeo 0.982409 punción espinal.Ampliar 0.373407 estudio clínico 0.337757 National Cancer Institute 0.329628	siguientes riesgos 0.321782 Instituto Nacional 0.357335 PDQ Tratamiento 0.392525 determinados cambios 0.326515 gen rela 0.670707 nuevos tipos 0.348217 siguientes factores 0.370167 sistema nervioso central 0.663463 Physician Data Query 0.423559 segura.ampliar craneotomía 0.353248 cuánto tumor 0.478632 siguientes sumarios 0.438618	CLICK HERE
2067	National Cancer Institute	Html	es	Terapia hormonal para el cáncer de seno	Hoja informativa que describe la terapia hormonal y su función en la prevención y tratamiento del cáncer de seno. Incluye información acerca de los efectos secundarios posibles y de los fármacos que pueden interferir con la terapia hormonal.	Surgical Adjuvant Breast 0.34336 Lancet Oncology 0.360626 Sestak I 0.320955 seno her2 y HR 0.354769 endocrine-responsive early breast 0.32332 endocrine therapy 0.324855 Preventing breast 0.319374 advanced breast 0.370204 Adjuvant hormonal therapy 0.333366 Cuzick J 0.320795 Vogel VG 0.310952 as adjuvant treatment 0.327521 efectos agonistas 0.311137 combined survival analysis 0.309596 Pippen J 0.31114 randomized trial comparing 0.312309 Collaborative Group 0.311107 seno hr 0.420398 hormonal therapy 0.348519 PubMed Abstract 0.906244 Surgical Oncology Clinics 0.312057 Clinical Oncology 0.330375 with advanced breast 0.322297 prior endocrine therapy 0.310537 early breast cancer 0.522236	alto riesgo 0.314676 hormonas estrógeno 0.407972 Bowel Project 0.309666 Wickerham DL 0.323539 aromatasa anastrozol 0.350666 initial adjuvant therapy 0.311523 Breast Cancer Group 0.336508 Costantino JP 0.33801 P-2 Trial 0.309919 Bowel Project Study 0.309651 seno er 0.390638 developing invasive breast 0.321634 standard hormonal therapy 0.329685 adjuvant endocrine therapy 0.312843 Italian Tamoxifen Anastrozole 0.312927 breast cancer 0.858969 Breast Cancer Trialists 0.369705 IBIS-I breast 0.319452 Forbes JF 0.31136 enzima llamada 0.312883 tamoxifen treatment 0.320843 Cancer Institute 0.344896 seno her2 0.38128 primary breast 0.320324	CLICK HERE
3576	National Cancer Institute	Html	en	Cancer Prevention Research	NCI’s prevention research has a broad focus, from identifying environmental and lifestyle factors that influence cancer risk to studying the biology of how cancer develops and studying ways to disseminate prevention interventions.	potential preventive therapies 0.441911 cancer prevention trials 0.552513 Drug Development Program 0.440287 PREVENT Cancer Preclinical 0.524374 higher cancer rates 0.5328 public health imperative 0.449962 Tobacco Control Research 0.447635 tobacco control programs 0.463087 invasive cancer 0.460548 specific population groups 0.436493 behavioral risk factors 0.665388 cancer care 0.47747 NCI’s Division 0.485356 cervical cancer 0.456337 Reduce Cancer Health 0.518587 FDA-approved HPV vaccines—work 0.439068 NCI’s Center 0.488421 Cancer Epidemiology 0.455548 prevention-focused clinical studies 0.444916 cancer health disparities 0.673431 Cancer Control 0.456877 risk reduction 0.469434 cancer screening 0.48636 cancer prevention 0.875489	United States 0.669252 new cancer prevention 0.553181 annual cancer-related deaths 0.450355 Cancer Research 0.477162 studies 0.468685 HPV-associated cancer 0.458082 cancer researchers 0.479223 substantially increased risk 0.487266 prevention research efforts 0.4695 HPV vaccine trials 0.440028 NCI Community Oncology 0.488471 new preventive therapy 0.454621 cancer development 0.485138 people 0.446203 cancer prevention research 0.671334 cancer disparities 0.497724 physical activity 0.439301 bivalent HPV vaccine 0.436545 Cancer Prevention Clinical 0.54727 NCI Cohort Consortium 0.479534 cancer risk 0.971388 cancer 0.983944 cancer incidence 0.537166 genome-wide association studies 0.438797	CLICK HERE
15584	National Cancer Institute	Html	en	Childhood Cancer Genomics (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.	childhood cancers 0.451916 genomic landscape 0.448565 leukemia cell lines 0.468388 Leukemia Group study 0.460885 Pediatric Acute Myeloid 0.449186 B-cell precursor 0.478228 childhood B-cell precursor 0.465086 B-acute lymphoblastic leukemia 0.506359 poor prognosis 0.440387 mutations 0.5002 children 0.490055 acute lymphoblastic leukaemia 0.700198 specific mutations 0.439289 AML 0.440256 Childhood Acute Lymphoblastic 0.50969 acute lymphoblastic leukemias 0.496998 chromosomal abnormalities 0.446518 CEBPA mutations 0.439533 oncology group study 0.489092 leukemia development 0.4551 B-precursor Acute Lymphoblastic 0.495043 patients 0.462491 prognostic significance 0.476271 Nat Genet 0.458917 Hyperdiploid leukemia cells 0.465322	childhood cancer 0.441528 et al. 0.603959 lymphoblastic leukemia interacts 0.498545 high-risk acute 0.4447 pre-B cell leukemia 0.456422 Pediatr Blood Cancer 0.444419 acute myeloid leukemia 0.542492 Moorman AV 0.468863 acute lymphocytic leukemia 0.496126 acute lymphoblastic leukaemias 0.511116 favorable prognosis 0.439188 point mutations 0.44293 B-acute lymphoblastic leukaemia 0.466866 cases 0.445244 genomic alterations 0.438134 Abstract 0.573806 Clin Oncol 0.509945 favorable outcome 0.455497 blood 0.45817 Acute promyelocytic leukemia 0.495963 pathogenic germline mutations 0.450974 acute lymphoblastic leukemia 0.983229 acute leukemia 0.50127 Mullighan CG 0.471025	CLICK HERE
15877	National Cancer Institute	Html	es	Antineoplastones (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer.	corta duración 0.52325 suficientes antineoplastones 0.570315 Centro Nacional 0.534282 New Hampshire Avenue 0.523956 cabo ensayos 0.607081 Drug Administration 0.514884 antineoplastones a10 0.621411 NCI Best Case 0.546794 siguientes tipos 0.528576 PDQ Antineoplastones 0.580269 datos bibliográficos pubmed 0.525907 siguientes preguntas 0.515649 fase ii 0.701787 células tumorales animales 0.553458 National Cancer Institute 0.529942 siguientes riesgos 0.520138 seguro médico 0.513988	Instituto Nacional 0.710175 Salud Complementaria 0.553301 Visuals Online 0.517781 complementarias revisa 0.52541 Physician Data Query 0.604461 antineoplastones a2 0.575169 Estados Unidos 0.855832 corto plazo 0.520833 libre uso 0.517405 página manejo 0.516526 ¿El tratamiento 0.536286 Clínica Mayo 0.524069 ¿Los beneficios 0.515122 juntos cam 0.514422 Series Program 0.514906 medicina complementaria 0.99587	CLICK HERE